Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "hyperplasia" wg kryterium: Temat


Wyświetlanie 1-2 z 2
Tytuł:
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency – management and differentiation in adults
Autorzy:
Nowak, Anna
Powiązania:
https://bibliotekanauki.pl/articles/1066263.pdf
Data publikacji:
2019
Wydawca:
Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:
21-hydroxylase
androgens
congenital adrenal hyperplasia
glucocorticosteroids
Opis:
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is one of the most common autosomal recessive hereditary diseases. The lack of cortisol synthesis leads to excessive stimulation of the adrenal glands by adrenocorticotropic hormone (ACTH). Moreover the impairment of cortisol synthesis results in adrenal hyperplasia and excessive androgen synthesis. Congenital adrenal hyperplasia is characterised by a considerable correlation between the genotype and the phenotype with the type of CYP21A2 gene mutation affecting the severity of 21-hydroxylase deficiency. The clinical manifestations of congenital adrenal hyperplasia in adults result from adrenocortical insufficiency, hyperandrogenism, and the adverse effects of glucocorticosteroids, which are used for the treatment of the syndrome. Non-classic congenital adrenal hyperplasia may sometimes have no clinical manifestation. Patients with classic congenital adrenal hyperplasia experience a wide variety of symptoms, including obesity, hypertension, hyperinsulinaemia, insulin resistance, and hyperleptinaemia. These abnormalities, the same as glucocorticosteroid treatment, promote the development of other diseases, such as metabolic syndrome, diabetes mellulitis, cardiovascular diseases and psychosocial problems. Moreover glucocorticosteroids treatment increases risk of osteoporosis and dermatological disorders. The maladies are more often seen in patients suffering from congenital adrenal hyperplasia syndrome than in the general population. Patients suffering from congenital adrenal hyperplasia require systematic evaluation of biochemical parameters (17-hydroxyprogesterone and androstendion) the same as clinical parameters (body mass index, waist circumference, glucose, lipids, blood pressure). Medical care for patients suffering from congenital adrenal hyperplasia should be provided by reference centres. Patients require cooperation between an endocrinologist, diabetologist, gynaecologist, andrologist, urologist, sexuologist and psychologist.
Źródło:
World Scientific News; 2019, 130; 71-81
2392-2192
Pojawia się w:
World Scientific News
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Thermobalancing therapy as a self-management tool
Autorzy:
Allen, Simon
Powiązania:
https://bibliotekanauki.pl/articles/1076998.pdf
Data publikacji:
2019
Wydawca:
Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:
benign prostatic hyperplasia
chronic prostatitis
disease management
kidney stone
thermobalancing therapy
Opis:
People live with one or more chronic diseases, medical and surgical treatments of which may affect their quality of life negatively. Thermobalancing therapy (TT) and Dr Allen’s therapeutic Devices (DATD) for the first time uses own body energy to treat chronic internal diseases. This invention received a US patent. Here we observe condition of people with benign prostatic hyperplasia (BPH), kidney stone disease and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) before and after use of TT and DATD. 10 years of empirical evidence has been studied in people with kidney disease, CP/CPPS and BPH. 2 clinical controlled trials on TT with DATD were conducted. The dynamics of clinical characteristics and parameters, such as pain, urinary symptoms and ultrasound prostate volume (PV), were compared with the no-treatment control groups. 124 men with BPH and 45 men with CP/CPPS used DATD for 6-month period, as mono-therapy, in clinical trials. The outcomes confirmed that TT with DATD reduced pain and PV in men with CP/CPPS and PV and urinary symptoms in men with BPH, while there were no positive changes in the control groups. 4 people with kidney stones, random from the 10-year follow-up, confirmed that after using DATD kidney stones were dissolved without side effects and complications. DATD is a class-1 medical device, which do not need an involvement of notified body, and it is easy use this device. Therefore, people with kidney stones, CP/CPPS and BPH should use DATD, as a tool for self-management in the first place.
Źródło:
World News of Natural Sciences; 2019, 23; 84-93
2543-5426
Pojawia się w:
World News of Natural Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies